Patients who have HCV infection are at high risk for arthralgia, myalgias, pruritus, neuropathy, and decompensated livers. Until recently the sole available treatment was interferon. After the US Food and Drug Administration (FDA) approved ribavirin, patients who took ribavirin plus interferon responded better. Now, the FDA has approved a small selection of oral antivirals to treat hepatitis C.
A national clinical trial has found non-efavirenz antiretroviral therapy effective as a first-line treatment, which is good news for patients with HIV who are ineligible to use the common drug.
Despite previous research suggesting HIV patients have an increased likelihood of suffering from a heart attack, kidney failure, or cancer, Johns Hopkins Bloomberg School of Public Health investigators showed the age they encounter these conditions were similar to their uninfected counterparts.
Researchers have found that maintenance treatment with methadone or buprenorphine may help prevent hepatitis C infection among injection drug users, a population with the highest risk of infection of the virus.